Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CBX7 | O95931 | 1/20 | 0.37 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.37 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.37 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426735 | 0.90 | SMO (0.49) | SMOMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1061681 | 0.90 | CXCR3 (0.45) | CXCR3IDO1SMOMEN1KMT2A | |
| SCHEMBL13708822 | 0.87 | SMO (0.48) | CXCR3IDO1SMOMEN1KMT2A | |
| SCHEMBL10314590 | 0.87 | SMN1; SMN2 (0.48) | SMOMAPTCBX7CDYL2CDYL | |
| SCHEMBL12962848 | 0.85 | CXCR3 (0.47) | CXCR3IDO1SMOMEN1KMT2A | |
| SCHEMBL1060340 | 0.83 | SMO (0.60) | CXCR3IDO1SMOMEN1KMT2A | |
| SCHEMBL3430411 | 0.82 | SMO (0.42) | SMOMAPTSMN1; SMN2 | |
| SCHEMBL1056839 | 0.80 | KMT2A (0.49) | SMOMEN1KMT2AMAPT | |
| SCHEMBL10004581 | 0.79 | SMO (0.49) | SMOMEN1KMT2A | |
| SCHEMBL10004576 | 0.78 | LMNA (0.51) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015705-B | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2013-11-13 | — | — | CN | disclosed |
| US-8217176-B2 | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| CN-102015705-A | Fused heterocyclic derivative and use thereof | TAKEDA PHARMACEUTICAL | 2011-04-13 | — | — | CN | disclosed |
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227561-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | SMO, NR1H2, NR1H4 | CXCR3 1510/4885IDO1 1264/4885SMO 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.